Interestingly, although inhibition of TGF-β signaling that targets CAFs is a promising strategy to enhance efficacy of cancer immunotherapies, systemic adverse effects and the therapeutic index of TGF-β inhibitor need careful consideration (55). The gene discussed is TGFB1; the disease is cancer.